New risk group staging according to new R-IPSS of 25 patients with low-risk MDS

被引：0
|
作者：
Tatic, A. [1 ]
Jardan, C. [1 ]
Georgescu, O. [1 ]
Stanca, O. [2 ]
Vasilica, M. [1 ]
Badelita, S. [1 ]
Crisan, A. M. [1 ]
Colita, A. [1 ]
Colita, D. [1 ]
Vulcan, G. [3 ]
Lupu, A. R. [2 ]
Coriu, D. [1 ]
机构：
[1] Fundeni Clin Inst, Prof Dr Stefan Berceanu Dept, Hematol & Bone Marrow Transplant, Bucharest, Romania
[2] Coltea Hosp, Dept Hematol, Bucharest, Romania
[3] Hiperdia, Brasov, Romania
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70215-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-167
引用
收藏
页码：S98 / S99
页数：2
相关论文
共 50 条
  • [1] LYMPHOPENIA IS AN INDEPENDENT RISK-FACTOR IN PATIENTS WITH LOW-RISK MDS ACCORDING TO THE IPSS-R
    Silzle, T.
    Schuler, E.
    Hildebrandt, B.
    Blum, S.
    Haas, R.
    Germing, U.
    HAEMATOLOGICA, 2017, 102 : 263 - 263
  • [2] The Natural History of Lower Risk MDS: Factors Predicting Progression to HighRisk Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Very Low and Low Risk MDS According to the R-IPSS Criteria
    Jain, Akriti G.
    Ball, Somedeb
    Aguirre, Luis E.
    Al Ali, Najla
    Kaldas, David
    Tinsley-Vance, Sara
    Kuykendall, Andrew T.
    Chan, Onyee
    Sweet, Kendra
    Lancet, Jeffrey E.
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami S.
    BLOOD, 2021, 138
  • [3] Time Dependent Platelet Attrition Identifies Biological Subgroup In Intermediate But Not Low-Risk Myelodysplastic Syndrome (MDS) Revised-IPSS (R-IPSS) Exhibiting Distinct Overall Survival
    Rivero, Gustavo A.
    Otazo, Maria
    Yellapragada, Sarvari Venkata
    Li, Ang
    Zheng, Matthew
    Perez, Ruben Hernandez
    Mims, Martha
    BLOOD, 2013, 122 (21)
  • [4] IMPACT OF TREATMENT ON OVERALL SURVIVAL IN PATIENTS WITH INTERMEDIATE-RISK MDS ACCORDING TO IPSS-R
    Perez Clara, Aparicio
    Rodriguez Elena, Paumard
    Ana Camila, Gonzalez Teomiro
    Camacho Inmaculada, Fernandez
    Hernandez Francisco, Salas
    Calvo Carmen, Martin
    Francisco Javier, Casano Sanchez
    Lopez Josefina, Serrano
    Garcia Joaquin, Sanchez
    HAEMATOLOGICA, 2021, 106 (10) : 250 - 250
  • [5] Clonal Evolution in Patients with Low-Risk MDS
    Mazzeo, P.
    Ganster, C.
    Brzuszkiewicz, E. B.
    Rittscher, K.
    Kamper, M.
    Goetze, K.
    Mueller-Thomas, C.
    Balaian, E.
    Sockel, K.
    Platzbecker, U.
    Shirneshan, K.
    Haase, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 36 - 36
  • [6] Effectiveness of tiotropium in low-risk patients according to new GOLD severity grading
    Halpin, David
    Decramer, Marc
    Celli, Bart
    Martin, Antonio
    Leimer, Inge
    Metzdorf, Norbert
    Tashkin, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [7] Cytogenetic abnormalities in primary MDS: Incidence and classification according to cytogenetic risk groups defined by the IPSS and IPSS-R
    Silva, M.
    Azevedo Neto, R.
    Leal, A.
    Ferreira, P.
    Kumeda, C.
    Tanizawa, R.
    Mascarenhas, A.
    Lima, W.
    Buccheri, V.
    Velloso, E.
    LEUKEMIA RESEARCH, 2013, 37 : S71 - S71
  • [8] Lymphopenia is highly prevalent in MDS and provides prognostic information for IPSS-R (very)-low-risk patients. An analysis from the EU-MDS registry
    Silzle, T.
    Taylor, A.
    de Witte, T.
    Malcovati, L.
    Fenaux, P.
    Bowen, D.
    Symeonidis, A.
    Stauder, R.
    Cermak, J.
    Sanz, G.
    Hellstrom-Lindberg, E.
    Langemeijer, S.
    Holm, M. Skov
    Madry, K.
    Tatic, A.
    de Almeida, A. Medina
    Savic, A.
    Smoljanovic, I. Mandac
    Germing, U.
    Smith, A.
    SWISS MEDICAL WEEKLY, 2021, 151 : 30 - 30
  • [9] Diagnosis of immune pathophysiology in patients with low-risk MDS
    Nakao, S.
    LEUKEMIA RESEARCH, 2009, 33 : S1 - S1
  • [10] TRANSFUSION BURDEN AMONG LOW-RISK MDS PATIENTS
    Dubow, J.
    Guerci, A.
    Gyan, E.
    Dupuis-Sireva, A.
    LEUKEMIA RESEARCH, 2021, 108 : S27 - S27
12345